Results of a detailed study of the clinical features, histology, management, and prognosis of palatal carcinoma of salivary origin in 30 patients are presented. These were compared to a larger series of salivary carcinoma at other sites, and to the known behavior of epidermoid carcinoma of the palate. The prognosis was significantly better for lesions of the palate. Results of treatment were also much better for these salivary gland lesions than for epidermoid carcinoma of the palate. The frequent occurrence and seemingly greater malignancy of adenoid cystic carcinoma at this anatomic site are stressed. Several patients with primary bone involvement survived, but local recurrence in the maxilla carried a graver prognosis. There was no definite indication that radiotherapy altered the course of the disease, and nothing to suggest that prophylactic neck dissection is of value. On the basis of the evidence presented, there is little to justify more radical excision than the clinical extent of the lesion would indicate, with the probable exception of adenoid cystic carcinoma, where a more aggressive approach may well prevent death from cancer.
Download full-text PDF |
Source |
---|
Skinmed
January 2025
Department of Dermatology, Medical Center, Bronx, NY;
The 73-year-old non-Hispanic, African-American man with a history of renal cell carcinoma (RCC), status post-nephrectomy receiving Lenvatinib, and metastatic disease, for which he also had received nivolumab for 13½ months. An itchy eruption appeared one month after the discontinuation of nivolumab and after the beginning of axitinib therapy. Physical examination revealed pink-violaceous scaly plaques, some with trailing scales on the anterior aspect of the trunk (Figure 1), a slight erosion on the hard palate, and hypopigmentation on the hands and legs.
View Article and Find Full Text PDFGenet Res (Camb)
December 2024
Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Nanfang Medical University, Guangzhou 510515, China.
The transcriptional regulatory factors binding to the polymorphic site C-1888T in the promoter region of the palate, lung, and nasal epithelium clone (PLUNC) gene were identified to investigate whether the C-1888T polymorphic site affects the transcriptional regulation and function of PLUNC gene. Three genotypes of C-1888T polymorphic locus were screened from established nasopharyngeal carcinoma (NPC) cells, and the mRNA expression levels of PLUNC gene in different genotypes were detected. The respective transcription factors that were more likely to bind with A or G in SNP were predicted by biological information and preliminarily verified in vitro by gel electrophoresis migration rate analysis.
View Article and Find Full Text PDFLin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
January 2025
J Stomatol Oral Maxillofac Surg
December 2024
Faculty of Medicine, Jordan University of Science & Technology, Irbid, Jordan. Electronic address:
Background: Oral cancer, particularly mucoepidermoid carcinoma (MEC), presents diagnostic challenges due to its histological diversity and rarity. This study aimed to develop machine learning (ML) models to predict survival outcomes for MEC patients and pioneer a clinically accessible prognostic tool.
Methods: Using the SEER database (2000-2020), we constructed predictive models with five ML algorithms: Random Forest Classifier (RFC), Gradient Boosting Classifier (GBC), Logistic Regression (LR), K-Nearest Neighbors (KNN), and Multilayer Perceptron (MLP).
J Craniofac Surg
January 2025
Department of Plastic and Reconstructive Surgery, The University of Tokyo.
Midface deformities due to oncologic bony defects are often difficult to secondarily correct. The authors herein report 2 cases of secondary reconstruction of an oncological premaxillary defect using a π-shaped fibula osteocutaneous flap. The authors divided the fibula into 3 pieces and made it π-shaped to reconstruct the curvature of the premaxilla.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!